Literature DB >> 10428939

Antitrypanosomal activity of fluoroquinolones.

E Nenortas1, C Burri, T A Shapiro.   

Abstract

Six fluoroquinolones presently in clinical use and four investigational tetracyclic fluoroquinolones were tested for in vitro activity against bloodstream-form Trypanosoma brucei brucei. All compounds had measurable activity, but the tetracyclic analogs were most potent, with 50% effective concentrations in the low micromolar range. In general, trypanosomes were more susceptible than L1210 leukemia cells. Consistent with the notion that they target type II topoisomerase in trypanosomes, the fluoroquinolones promote the formation of protein-DNA covalent complexes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428939      PMCID: PMC89417     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  High-efficiency clonal growth of bloodstream- and insect-form Trypanosoma brucei on agarose plates.

Authors:  V B Carruthers; G A Cross
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

Review 2.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

3.  Potent antibacterial fluoroquinolones with marked activity against Leishmania donovani in vivo.

Authors:  W Raether; H Seidenath; J Hofmann
Journal:  Parasitol Res       Date:  1989       Impact factor: 2.289

4.  Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.

Authors:  J Pépin; F Milord; A Khonde; T Niyonsenga; L Loko; B Mpia
Journal:  Trans R Soc Trop Med Hyg       Date:  1994 Jul-Aug       Impact factor: 2.184

Review 5.  The structure and replication of kinetoplast DNA.

Authors:  T A Shapiro; P T Englund
Journal:  Annu Rev Microbiol       Date:  1995       Impact factor: 15.500

6.  Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs.

Authors:  T A Shapiro; P T Englund
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

Review 7.  Human African trypanosomiasis: an emerging public health crisis.

Authors:  D H Smith; J Pepin; A H Stich
Journal:  Br Med Bull       Date:  1998       Impact factor: 4.291

8.  Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.

Authors:  J L Nitiss; Y X Liu; P Harbury; M Jannatipour; R Wasserman; J C Wang
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

9.  Antitrypanosomal activity of camptothecin analogs. Structure-activity correlations.

Authors:  A L Bodley; M C Wani; M E Wall; T A Shapiro
Journal:  Biochem Pharmacol       Date:  1995-09-28       Impact factor: 5.858

10.  Drug cytotoxicity assay for African trypanosomes and Leishmania species.

Authors:  A L Bodley; M W McGarry; T A Shapiro
Journal:  J Infect Dis       Date:  1995-10       Impact factor: 5.226

View more
  8 in total

Review 1.  State of the art in African trypanosome drug discovery.

Authors:  Robert T Jacobs; Bakela Nare; Margaret A Phillips
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

2.  Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes.

Authors:  Sonya C Tang; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

3.  Antitrypanosomal activities of fluoroquinolones with pyrrolidinyl substitutions.

Authors:  Elizabeth Nenortas; Tomasz Kulikowicz; Christian Burri; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 4.  Novel lead compounds in pre-clinical development against African sleeping sickness.

Authors:  Michael Berninger; Ines Schmidt; Alicia Ponte-Sucre; Ulrike Holzgrabe
Journal:  Medchemcomm       Date:  2017-07-31       Impact factor: 3.597

Review 5.  Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery.

Authors:  Rafael Balaña-Fouce; Raquel Alvarez-Velilla; Christopher Fernández-Prada; Carlos García-Estrada; Rosa M Reguera
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-08-24       Impact factor: 4.077

Review 6.  Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?

Authors:  A Dalhoff
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

7.  Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.

Authors:  Melissa F Adasme; Sarah Naomi Bolz; Lauren Adelmann; Sebastian Salentin; V Joachim Haupt; Adriana Moreno-Rodríguez; Benjamín Nogueda-Torres; Verónica Castillo-Campos; Lilián Yepez-Mulia; José A De Fuentes-Vicente; Gildardo Rivera; Michael Schroeder
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

8.  1,2-substituted 4-(1H)-quinolones: synthesis, antimalarial and antitrypanosomal activities in vitro.

Authors:  Abraham Wube; Antje Hüfner; Werner Seebacher; Marcel Kaiser; Reto Brun; Rudolf Bauer; Franz Bucar
Journal:  Molecules       Date:  2014-09-10       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.